Abstract
The experience of the past dozen years clearly indicates that iron plays a significant role in the pathogenesis of a wide variety of disease states apart from hemochromatosis. 1 In cases of rheumatoid arthritis and reperfusion injury, iron catalyzes the formation of free radicals which destroy membranes and thereby lead to tissue damage. Sequestration of this iron would obviate much of this damage. In lymphopro-liferative disorders and parasitic diseases such as malaria, iron serves as an essential nutrient for dividing cells. Withholding iron would inhibit cell division and hence slow the progression of such diseases. While unlikely to affect cures, chelation of iron would undoubtedly be of benefit as adjunctive therapy in these and related disorders.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
C. Hershko, Iron chelators in medicine, Molec. Aspects Med. 13: 113 (1992).
P.J. Giardina, R.W. Grady, K.H. Ehlers, S. Burstein, J.H. Graziano, A.L. Markenson and M.W. Hilgartner, Current therapy of Cooley’s anemia: a decade of experience with subcutaneous desferrioxamine, Ann. N. Y. A. S. 612: 275 (1990).
R.W. Grady, and C. Hershko, HBED: a potential oral iron chelator, Ann. N. Y. A. S. 612: 361 (1990).
G.M. Brittenham, Pyridoxal isonicotinoyl hydrazone, effective iron chelation after oral administration, Ann. N. Y. A. S. 612: 315 (1990).
R.C. Hider, S. Singh, J.B. Porter, and E.R. Huehns, The development of hydroxypyridin-4-ones as orally active iron chelators, Ann. N. Y. A. S. 612: 327 (1990).
R.J. Bergeron, J. Wiegand, J.B. Dionis, M. Egli-Karmakka, J. Frei, A. Huxley-Tencer, and H.H. Peter, Evaluation of desferrithiocin and its synthetic analogues as orally effective iron chelators, J. Med. Chem. 34: 2072 (1991).
B.E. Hedlund, P.E. Hallaway, and J.R. Mahoney, High molecular weight forms of deferoxamine: novel therapeutic agents for treatment of iron-mediated tissue injury, Adv. Exp. Med. Biol. 264: 229 (1990).
R.J. Bergeron, J. Wiegand, J.S. McManis, and P.T. Perumal, Synthesis and biological evaluation of hydroxamate-based iron chelators, J. Med. Chem. 34: 3182 (1991).
N.F. Olivieri, D.M. Templeton, G. Koren, D. Chung, M.H. Freedman, and R.A. McClelland, Evaluation of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients, Ann. N. Y. A. S. 612: 369 (1990).
P. Tondury, G.J. Kontoghiorghes, A. Ridolfi-Luthy, A. Hirt, A.V. Hoffbrand, A.M. Lottenbach, T. Sonderegger, and H.P. Wagner, L1 (1,2-dimethyl-3-hydroxypyrid-4-one) for oral iron chelation in patients with ß-thalassemia, Br. J. Haematol. 76: 550 (1990).
M.B. Agarwal, S.S. Gupte, D. Vasandani, C. Viswanathan, R.R. Puniyani, J. Rananathan, D.E. Massil, S. Shah, G.C. Rajyadhyaksha, and A.A. Bhave, Efficacy and safety of 1,2-dimethyl-3-hydroxypyrid-4-one (L1) as an oral iron chelator in patients of ß-thalassemia major with iron overload, J. Assoc. Phys. (India) J. A. P. I. 39: 669 (1991).
F.N. Al-Refaie, B. Wonke, A.V. Hoffbrand, D.G. Wickens, P. Nortey, and G.J. Kontoghiorghes, Efficacy and possible adverse effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia major, Blood, 80: 593 (1992).
V. Berdoukas, P. Bentley, H. Frost and H.P. Schnebli, Tocicity of oral iron chelator L1, The Lancet, 341: 1088 (1993).
C. Hershko, Development of oral iron chelator L1, The Lancet, 341: 1088 (1993).
G.J. Kontoghiorghes, M.B. Agarwal, P. Tondury, M.J. Kersten, M. Jaeger, G. Vreugdenhil, A. Vania and Y.E. Rahman, Future of oral iron chelator deferiprone (L1), The Lancet, 341: 1479 (1993).
R.W. Grady, and A. Jacobs, The screening of potential iron chelating drugs, in: “Development of Iron Chelators for Clinical Use: Proceedings of the Second Symposium on the Development of Iron Chelators for Clinical Use,” A.E. Martell, W.F. Anderson and D.G. Badman, eds., Elsevier North Holland, Inc., New York (1981).
R.W. Grady, A.D. Salbe, M.W. Hilgartner and P.J. Giardina, Preliminary results from a phase I clinical trial of HBED, in: “The Development of Iron Chelators for Clinical Use,” R.J. Bergeron and G.M. Brittenham, eds., CRC Press, Inc., Boca Raton (1993).
C.M. Peterson, J.H. Graziano, R.W. Grady, R.L. Jones, H.V. Vlassara, V.C. Canale, D.R. Miller and A. Cerami, Chelation studies with 2,3-dihydroxybenzoic acid in patients with ß-thalassaemia major, Br. J. Haematol., 33: 477 (1976).
M.J. Pippard, S.T. Callender, and C.A. Finch, Ferrioxamine excretion in iron loaded man, Blood 60: 288 (1982).
J.A. Harris, and F.G. Benedict, A biometric study of basal metabolism in man, in: “Publication No. 279,” Carnegie Institution, Washington, D. C. (1919).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1994 Springer Science+Business Media New York
About this chapter
Cite this chapter
Grady, R.W., Hilgartner, M.W., Giardina, P.J., Salbe, A.D. (1994). Results from a Phase I Clinical Trial of HBED. In: Hershko, C., Konijn, A.M., Aisen, P. (eds) Progress in Iron Research. Advances in Experimental Medicine and Biology, vol 356. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-2554-7_37
Download citation
DOI: https://doi.org/10.1007/978-1-4615-2554-7_37
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6090-2
Online ISBN: 978-1-4615-2554-7
eBook Packages: Springer Book Archive